Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oded Icht

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics|July 13, 2024
Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual TrialElisha Fredman, Assaf Moore, Oded Icht, et al.
The Oncologist|April 4, 2023
Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort StudyOded Icht, Avi Leader, Erez Batat, et al.
Oncology|July 11, 2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerOded Jacobi, Yosef Landman, Daniel Reinhorn, et al.
Journal of the Neurological Sciences|June 29, 2021
Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitorsAssaf Moore, Shlomit Yust-Katz, Oded Icht, et al.
Asia-Pacific Journal of Clinical Oncology|August 8, 2020
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancerOded Icht, Liran Domachevsky, David Groshar, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter StudyItamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Thoracic Cancer|April 24, 2023
Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literatureItamar Averbuch, Roi Tschernichovsky, Oded Icht, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 10, 2025
The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapyInbar Nardi Agmon, Luna Jia Zhan, Gloria Ho, et al.
Journal of Neuro-Oncology|February 7, 2024
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatmentItamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 24, 2026
Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial - two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacingElisha Fredman, Mirona Attrash, Eyal Yosefof, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Radiation Oncology, Biology, Physics|July 13, 2024
Acute Toxicity and Early Prostate Specific Antigen Response After Two-Fraction Stereotactic Radiation Therapy for Localized Prostate Cancer Using Peri-Rectal Spacing-Initial Report of the SABR-Dual TrialElisha Fredman, Assaf Moore, Oded Icht, et al.
The Oncologist|April 4, 2023
Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort StudyOded Icht, Avi Leader, Erez Batat, et al.
Oncology|July 11, 2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerOded Jacobi, Yosef Landman, Daniel Reinhorn, et al.
Journal of the Neurological Sciences|June 29, 2021
Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitorsAssaf Moore, Shlomit Yust-Katz, Oded Icht, et al.
Asia-Pacific Journal of Clinical Oncology|August 8, 2020
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancerOded Icht, Liran Domachevsky, David Groshar, et al.
International Journal of Radiation Oncology, Biology, Physics|November 16, 2025
Assessment of the Effective Dose to Immune Cells as an Independent Predictor of Durvalumab Response in Patients With Non-Small Cell Lung Cancer After Chemoradiotherapy: A Multicenter StudyItamar Averbuch, Sarit Appel, Philip Blumenfeld, et al.
Thoracic Cancer|April 24, 2023
Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literatureItamar Averbuch, Roi Tschernichovsky, Oded Icht, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 10, 2025
The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapyInbar Nardi Agmon, Luna Jia Zhan, Gloria Ho, et al.
Journal of Neuro-Oncology|February 7, 2024
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatmentItamar Averbuch, Roi Tschernichovsky, Shlomit Yust-Katz, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 24, 2026
Two-year toxicity and PSA dynamics in the initial cohort of the SABR-Dual trial - two-fraction stereotactic radiotherapy for localized prostate cancer using rectal spacingElisha Fredman, Mirona Attrash, Eyal Yosefof, et al.
Pageof 3